Smart Immune Wins  Best Therapeutic Innovation and Oncology Upward Investmeant Awards at MATWIN

Paris, France, 19 May 2022: Smart Immune, clinical-stage biotechnology company focused on saving and improving lives by delivering to patients a new generation of Thymus-empowered T cell medicine, today announces it has won both “Best Therapeutic Innovation” and “Oncology Upward Investment (OUI)” awards duringthe last MEET2WIN European Oncology Partnering Convention organized by the MATWIN platform (May 2022).

MATWIN, a subsidiary of the Unicancer group (an association of all French Cancer Centers), is the only national program dedicated to accelerating early innovation in oncology. Its main objective is to support innovative projects with high development potential by promoting early industrial partnerships.

Smart Immune’s team presented its unique approach to treat blood cancer, using genetically modified and biomanufactured lymphoid progenitors to target malignant cells, to MATWIN’s international Board of oncology experts. The Company’s lead asset, Smart 101 ProTcellTM, is the first cellular therapy to be based on patients’ thymus function.

MATWIN winners received six months support from the MATWIN accelerator, benefiting from support from around 50 business experts, providing international visibility and a chance to boost development programs.

Karine Rossignol, CEO and Co-founder of Smart Immune, said: “We are thrilled that this major oncology body gave us the opportunity to showcase our transformative science.  These awards reinforce the hard work of the Smart Immune team, one that is fully dedicated to bringing therapeutic innovation to patients. We are very thankful to have received both these awards and for three days of fruitful meetings at MATWIN.”

Watch our new video which explains Smart Immune’s new treatment platform.

Read MATWIN’s full press release.

About Smart Immune

Smart Immune is a clinical stage biotechnology company based in Paris, France. It was created in 2017 by Marina Cavazzana, MD, PhD, Isabelle André, PhD, and Karine Rossignol, PharmD, to unlock the potential of Allogeneic T cell medicine and change the prognosis of patients with life-threatening diseases such as high-risk leukemia and primary immunodeficiencies.

Through its patented ex vivo lymphoid niche technology, Smart Immune develops a thymus empowered T cell therapy platform called ProTcell™. It has been designed to ensure a rapid, complete, and long-lasting immune recovery to fight malignancies and infections.

About MATWIN

MATWIN is a French open-innovation platform dedicated to promoting innovation in oncology. For over ten years, the platform has offered a six-month support program to help fast-track innovative projects – from both academic laboratories and startup companies across Europe – and promote partnerships with industrial partners and investors. The program is supported by 13 international laboratories (Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Exact Sciences, Gilead, GSK, Nanostring Technologies, Novartis, Pierre Fabre, Pfizer, Roche and Sanofi) as well as many other organizations working to promote innovation in cancer research (e.g. oncology clusters, technology transfer offices, incubators ...). Since 2015, MATWIN has been a subsidiary of Unicancer, the French federation that brings together the 18 Comprehensive Cancer Centers in France.

www.matwin.fr

Media contact:

Consilium Strategic Communications

smartimmune@consilium-comms.com

‍